Articles from CytoAgents, Inc.

CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid sparing inhibitor of prostaglandin mediated inflammation, announced today that preliminary safety data from its Phase 1b/2a clinical trial for its lead drug candidate, CTO1681, will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida.

CytoAgents, Inc., a clinical-stage biotechnology company developing a safe and effective preventative treatment for cytokine release syndrome (CRS) and the neurotoxicity immune effector cell-associated neurotoxicity syndrome (ICANS), announced today that it has been awarded a $2.25 million National Institutes of Health (NIH) grant, the fourth NIH grant totaling $7.85 million in five years.

CytoAgents, Inc., a clinical-stage therapeutics company developing a safe, effective treatment (CTO1681) for Cytokine Release Syndrome (CRS), today announced that it has strengthened its leadership team with the appointment of Arthur P. Bertolino MD, PhD, MBA, as Chief Medical Officer. Dr. Bertolino is a seasoned senior pharmaceuticals executive who has led clinical development and business growth for early-stage biotechnology as well as mid-sized and large pharmaceutical companies. Through extensive domestic and international management and drug development experience, including C-level roles in pharmaceuticals and boutique biotechnology, Dr. Bertolino combines science, medicine, and business administration, with leadership acumen and drive to efficiently deliver high-value pharmaceuticals.

CytoAgents, Inc., a clinical stage biotechnology company, announced today that its lead drug candidate, GP1681, has successfully completed Phase 1 clinical trials with a strong safety profile. Building on these positive results, the company also announced the close and oversubscription of an initial equity round and is now positioned to raise a larger Series A round in early 2022 to enable two Phase II trials. CytoAgents is developing innovative pharmaceutical products to treat life-threatening conditions, diseases and disorders associated with Cytokine Release Syndrome, or CRS. Commonly referred to as cytokine storm and clinically known as hypercytokinemia, CRS is a potentially lethal condition associated with a range of diseases and treatments.